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Abstract
The Metabolic Syndrome (MetSyn), which is a clustering of traits including insulin resistance, obesity,
hypertension and dyslipidemia, is estimated to have a substantial genetic component, yet few specific
genetic targets have been identified. Factor analysis, a sub-type of structural equation modeling (SEM),
has been used to model the complex relationships in MetSyn. Therefore, we aimed to define the genetic
determinants of MetSyn in the Framingham Heart Study (Offspring Cohort, Exam 7) using the
Affymetrix 50 k Human Gene Panel and three different approaches: 1) an association-based “one-SNP-
at-a-time” analysis with MetSyn as a binary trait using the World Health Organization criteria; 2) an
association-based “one-SNP-at-a-time” analysis with MetSyn as a continuous trait using second-order
factor scores derived from four first-order factors; and, 3) a multivariate SEM analysis with MetSyn as a
continuous, second-order factor modeled with multiple putative genes, which were represented by
latent constructs defined using multiple SNPs in each gene. Results were similar between approaches in
that CSMD1 SNPs were associated with MetSyn in Approaches 1 and 2; however, the effects of CSMD1
diminished in Approach 3 when modeled simultaneously with six other genes, most notably CETP and
STARD13, which were strongly associated with the Lipids and MetSyn factors, respectively. We
conclude that modeling multiple genes as latent constructs on first-order trait factors, most proximal to
the gene’s function with limited paths directly from genes to the second-order MetSyn factor, using SEM
is the most viable approach toward understanding overall gene variation effects in the presence of
multiple putative SNPs.
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The Metabolic Syndrome (MetSyn) is a clustering of
metabolic disturbances that increases the risk of type 2
diabetes and cardiovascular disease [1], and may
contribute to the pathogenesis of other complex dis-
eases, including cancer [2]. MetSyn is estimated to affect
over 47 million adult Americans [3,4] and is becoming
increasingly more prevalent worldwide [5,6]. Although
MetSyn has been shown to increase with age, recent
studies have shown a rise in this disease among younger
people in the U.S., particularly in women 20 to 39 years
of age [1]. Interestingly, this rise mirrors the increasing
rates of obesity in women of these ages.
Although it is well established that MetSyn involves the
co-occurrence of multiple metabolic traits, there are
differences in the formal definitions set forth by the
World Health Organization (WHO), the National
Cholesterol Education Program Third Adult Treatment
Panel (NCEP-ATP III), the American Heart Association/
National Heart, Lung and Blood Institute (AHA/NHLBI)
and the International Diabetes Federation (IDF), pre-
dominantly in defining the most relevant elements and
their biological cut-points, which has contributed to
confusion in the literature [7]. Nevertheless, all of these
definitions include criteria on four common traits:
1) insulin resistance, 2) obesity, 3) hypertension, and
4) dyslipidemia. Factor analysis, a statistical method
under the umbrella of structural equation modeling
(SEM), has been used, albeit sparingly, to help define the
critical elements and structure of the syndrome. Studies
conducted in adults using 8 to 10 metabolic measures
(fasting insulin, fasting glucose, post-challenge insulin,
post-challenge glucose, body mass index (BMI), waist
circumference or waist-to-hip ratio (WHR), high density
lipoprotein-cholesterol (HDL), triglycerides (TG), systo-
lic blood pressure (SBP), diastolic blood pressure (DBP))
have shown that the MetSyn is best described, statisti-
cally, as a unifying, second-order factor defined by four
first-order factors (Insulin Resistance, Obesity, Hyperten-
sion, Lipids) [8-10].
MetSyn is hypothesized to have fairly large genetic
component with heritability estimates ranging from
6.3% to 50% [11], yet few potential genetic targets
have been identified. Thus, we aimed to define the
genetic determinants of MetSyn in the Framingham
Heart Study (Offspring Cohort, Exam 7) using the
Affymetrix 50 k Human Gene Panel data and three
different approaches: 1) an association-based “one-
single-nucleotide polymorphism (SNP)-at-a-time” ana-
lysis with MetSyn defined as a binary trait using the
WHO criteria [7]; 2) an association-based “one-SNP-at-
a-time” analysis with MetSyn defined as a continuous
trait using second-order factor scores derived from
insulin resistance, obesity, hypertension, and dyslipide-
mia factors; and, 3) a multivariate SEM analysis with
MetSyn defined as a second-order continuous factor trait
modeled simultaneously with putative genes (identified
in Approaches 1 and 2), which we represented as latent
constructs defined by multiple SNPs within each gene.
Methods
Data cleaning and preparation: phenotype and
genotype variables
First, we examined the distribution of metabolic
variables (TG, HDL, SBP, DBP, fasting glucose, BMI) in
the Offspring Cohort, Exam 7 using SAS v9.1 (SAS
Institute Inc., Cary, NC). Variables not following a
normal distribution, as determined by visual inspection
of histograms and quantile-quantile plots and formal
Shapiro-Wilk’s and Kolmogorov-Smirnov tests, were
natural log transformed (TG, HDL, fasting glucose). To
adjust for potential bias by antihypertensive treatment
and more closely reflect pretreatment BP values, we
a d d e d1 0m mH gt oS B Pa n d5m mH gt oD B P ,
following Cui et al. [12], in subjects who reported taking
blood pressure medications. We used the WHO criteria
[7] to define MetSyn; however, waist circumference and
microalbuminuria measures were not available, and we
applied the most recent IDF fasting glucose cut-point
value of ≥100 mg/dL [7]. Mendelian inconsistencies were
identified in the Affymetrix 50 k Human Gene Panel data
using MARKERINFO (S.A.G.E. v5.4.1). If an inconsis-
tency was found, genotypes of all individuals in that
family were set to missing. Of the 2760 subjects in the
Offspring Cohort (Approach 1), 2544 had complete data
on all metabolic measures (Approach 2) and 1512 had
complete data on all metabolic measures and putative
genotypes (Approach 3).
Statistical methods for association-based analyses
Approach 1 and 2
We evaluated the potential association between each
SNP on the 50 k panel and each phenotype using the
following model [13] in ASSOC (S.A.G.E. v5.4.1):
hy h c c c z ii i n n i i i () ( ) , =+ + + + ++ αγ γ γ δ η 11 22 …
where for any individual i,w i t ht r a i tyi, cji is any one of n
individual specific covariates, hi is a random effect
comprising, in our analyses, the sibling and individual
specific errors, zi is a genotype indicator for allele A at a
diallelic locus with alleles A and B:
zi =
−1
0
1
for genotype BB  or
for genotype AB  or
for genotype 
;
;
A AA,
⎧
⎨
⎪
⎩
⎪
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tion [14], which estimates the regression coefficients, gj
and δ, as median unbiased on the original scale of
measurement. Analyses were adjusted for age, sex and
age × sex. p-Values were calculated using likelihood-ratio
a n dW a l dt e s t sa n dc o m p a r e dt oe n s u r ec o n s i s t e n c y ;
however, we report only the Wald p-values since results
were similar in all cases. In Approach 1 and 2, a gene was
considered statistically significant if it had ≥2 SNPs
associated with an individual metabolic variable or
MetSyn at p < 0.001. Significant genes were then utilized
in Approach 3.
Statistical methods for factor analysis (FA) and SEM
Approach 2 and 3
We used previous reports to devise our second-order
MetSyn factor model [9,10]; however, because fasting
insulin and waist circumference were not available, first-
order factors, Insulin Resistance and Obesity were
defined using only fasting glucose and BMI, respectively.
Similar to previous models [9,10], the BP and Lipids
first-order factors were defined using SBP and DBP and
TG and HDL measures, respectively. We performed
confirmatory factor analysis using a robust maximum
likelihood estimator (MLR), which provides test statistics
and standard errors robust to non-independence of
observations and non-normality (Mplus v5.1; TYPE =
COMPLEX), to formally test our second-order MetSyn
model and to generate corresponding factor scores. In
Approach 2, we examined potential associations
between each SNP on the 50 k panel and the factor
scores with ASSOC (S.A.G.E. v5.4.1). In Approach 3, we
extended the latent gene construct SEM method of Nock
et al. [15] using the robust maximum likelihood
estimator (MLR; Mplus v5.1) to simultaneously model
MetSyn as a second-order factor together with multiple
putative genes identified in Approaches 1 and 2. Similar
to Nock et al. [15], we used eigenvalues, scree plots,
factor patterns, Cronbach’s alpha and linkage disequili-
brium (LD) plots (Haploview v4.1) to help select the
most informative SNPs in devising the latent gene
constructs. For putative genes identified in Approaches 1
and 2, we utilized all available SNPs on the 50 k panel,
including those SNPs found to be statistically significant
in Approaches 1 and 2, unless they provided redundant
information and created a linear dependency. To assess
the overall model goodness-of-fit to the data, the c
2 test,
comparative fit index (CFI), root mean square error of
approximation (RMSEA) and standardized root mean
square residual (SRMR) were evaluated [16]. The c
2 test,
which evaluates whether the covariance matrix is equal
to the model-implied covarian c em a t r i xp r e d i c t e db yt h e
parameters, is very sensitive to sample size and complex-
ity. Thus, other fit indices such as the CFI, RMSEA, and
SRMR have been proposed as alternative descriptive
measures for evaluating model fit [16]. Values for the
CFI, which is relatively insensitive to sample size and
model complexity, of ≥0.90 and ≥0.95 indicate accep-
table and good fit, respectively [17]. Values for the
RMSEA (an index less sensitive to sample size and
favoring more parsimonious models) values of ≤0.06
represent good fit while values >0.10 represent unac-
ceptable fit [17]. A SRMR ≤0.08 and <0.10 represent
good and acceptable fit, respectively [16,17]. All p-values
are from two-sided tests and statistical significance set at
p ≤ 0.05 in Approach 3.
Results
In Approach 1, we evaluated the potential associations
between each SNP on the Affymetrix 50 k Human Gene
Panel and MetSyn as a binary trait defined using the
modified WHO criteria (see Methods) and between each
SNP and each individual metabolic measure. We found
that several genes had two or more SNPs with significant
(p < 0.001) associations, the majority of which are listed
in Table 1. Of these genes, the most significant associa-
tions were observed with CETP SNPs rs11508026 (p =
7.60 × 10
-7) and rs3764261 (p = 1.34 × 10
-6). Two of the
same KIAA0329 SNPs (rs12434098, rs1190547) were
associated with TG and HDL but not with MetSyn.
Multiple CSMD1 SNPs were associated with BMI and
MetSyn, while WDR64 SNPs were associated with SBP
and MetSyn.
In Approach 2, we modeled MetSyn as a continuous,
second-order factor defined by four first-order factors
(Obesity, Insulin Resistance, BP, Lipids) and observed a
good fitting model by several fit indices (c
2 = 59.48, df = 7,
p < 0.05; CFI = 0.97; RMSEA = 0.05; SRMR = 0.02). We
found Insulin Resistance was the most important factor
(bstd = 0.99 ± standard error of bstd =0 . 0 2 ;p <0 . 0 0 1 )
followed by Obesity (0.96 ± 0.03; p <0 . 0 0 1 ) ,L i p i d s
(0.69 ± 0.05; p < 0.001), and BP (0.50 ± 0.04; p <0 . 0 0 1 ) .
Using this model, we examined potential associations
between each SNP on the 50 k panel and the second- and
first-order factor scores (Table 2). KIAA0329 SNPs were
found to be associated with Lipids factor scores (Table 2),
which is consistent with the results observed in Approach 1
in that KIAA0329 SNPs were also associated with TG and
HDL measures. However, CSMD1 was the only gene with
≥2 SNPs found to be associated with MetSyn factor scores
(p < 0.001). In Approach 3, we extended the latent gene
construct SEM method of Nock et al. [15] to model
multiple putative genes identified in Approaches 1 and 2
simultaneously with MetSyn as a second-order factor
modeling MetSyn as second-order factor with 24 SNPs in
seven genes improved model fit by several indices (c
2 =
523.52, df = 375, p < 0.05; CFI = 0.99; RMSEA = 0.01;
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2 of MetSyn from 0.23 to
0.43, compared to the same model without genes. To
further illustrate the utility of SEM, we also added a path
between MetSyn and coronary heart disease (CHD) in
models with and without genes. As shown in Figure 1, the
strongest associations in terms of effect size and statistical
significance were found between CETP and Lipids (bstd =
0.15 ± 0.02; p =1 . 0 4×1 0
-8), STARD13 and Insulin
Table 1: Genes with ≥ 2 SNPs associated with individual metabolic measures and MetSyn
a at p <0 . 0 0 1
Trait and Chr Gene
symbol
Gene ID rs number Base pair/AA change MAF b (S.E.) p-Value
Fasting glucose
Chr 13 STARD13 90627 515192 Outside G/T 0.400 0.034 (0.009) 0.000266
STARD13 90627 2858808 Intron C/T 0.364 0.032 (0.009) 0.000808
BMI
Chr 4 KCTD8 386617 13143747 Thr/Thr 0.092 -1.612 (0.419) 0.000118
KCTD8 386617 17599556 Intron A/C 0.142 -0.978 (0.276) 0.000371
KCTD8 386617 2347926 Intron A/C 0.242 -1.066 (0.299) 0.000400
Chr 8 CSMD1 64478 1997137 Intron G/T 0.167 0.944 (0.281) 0.000284
CSMD1 64478 2930355 Intron A/G 0.183 1.241 (0.342) 0.000778
Chr 13 - 729646 311865 Outside C/T 0.267 1.293 (0.265) 0.000001
- 729646 1006255 Outside C/T 0.417 -0.933 (0.240) 0.000102
TG
Chr 14 KIAA0329 9895 1210074 Intron A/G 0.246 0.093 (0.027) 0.000462
KIAA0329 9895 12434098 Intron C/T 0.475 0.101 (0.029) 0.000682
KIAA0329 9895 1190547 Intron C/G 0.242 0.091 (0.028) 0.000966
HDL
Chr 14 KIAA0329 9895 12434098 Intron C/T 0.475 -0.050 (0.014) 0.000322
KIAA0329 9895 1190547 Intron C/G 0.242 -0.049 (0.014) 0.000637
Chr 16 CETP 1071 11508026 Intron C/T 0.492 -0.075 (0.016) 7.60 × 10
-7
CETP 1071 3764261 Outside G/T 0.367 -0.069 (0.014) 1.34 × 10
-6
SBP
Chr 1 WDR64 128025 12074374 Trp/Arg 0.208 -4.271 (1.207) 0.000246
WDR64 128025 12095445 Gln/Arg - -4.390 (1.197) 0.000402
Chr 13 MYO16 23026 4772992 Intron A/G 0.383 -2.895 (0.876) 0.000158
MYO16 23026 6492144 Intron C/G 0.392 -2.964 (0.785) 0.000777
MYO16 23026 9514889 Intron A/G 0.192 -2.673 (0.795) 0.000953
MetSyn
a
Chr 1 WDR64 128025 12074374 Trp/Arg 0.208 -0.060 (0.018) 0.000721
WDR64 128025 12095445 Gln/Arg - -0.061 (0.018) 0.000961
Chr 8 CSMD1
b 64478 7013078 Intron A/C 0.040 -0.135 (0.039) 0.000582
CSMD1 64478 12549291 Intron G/T 0.250 0.045 (0.013) 0.000808
aMetSyn defined as binary trait using a modified WHO definition (see text).
brs1997137 and rs2930355 in CSMD1 were associated with MetSyn at p = 0.007 and p = 0.003, respectively.
Table 2: Genes with ≥ 2 SNPs associated with MetSyn factor scores
a at p <0 . 0 0 1
Trait and Chr Gene
symbol
Gene ID rs number Base pair
change
MAF b (S.E.) p-value
Insulin resistance (first-order factor)
Chr 8 CSMD1 64478 7013078 Intron A/C 0.040 -4.724 (1.392) 0.000594
CSMD1 64478 1997137 Intron G/T 0.167 2.572 (0.755) 0.000623
Obesity (first-order factor)
Chr 8 CSMD1 64478 1997137 Intron G/T 0.167 0.674 (0.194) 0.000469
CSMD1 64478 7013078 Intron A/C 0.040 -1.222 (0.360) 0.000510
Lipids (first-order factor)
b
Chr 14 KIAA0329 9895 1210074 Intron A/G 0.246 0.230 (0.063) 0.000285
KIAA0329 9895 12434098 Intron C/T 0.475 0.211 (0.060) 0.000420
KIAA0329 9895 1190547 Intron C/G 0.242 0.304 (0.129) 0.000585
MetSyn (second-order factor)
a
Chr 8 CSMD1 64478 1997137 Intron G/T 0.167 0.189 (0.056) 0.000583
CSMD1 64478 7013078 Intron A/C 0.040 -0.428 (0.103) 0.000632
aScores from a second-order, MetSyn factor model (factors shown in blue text only in Figure 1 depict a similar model).
bNo genes with two or more SNPs were found to be associated with the BP first-order factor at p < 0.001.
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(page number not for citation purposes)Resistance (bstd = 0.14 ± 0.08; p =0 . 0 5 ) ,a n dSTARD13 and
MetSyn (bstd = 0.08 ± 0.03; p = 0.007); however, the
CSMD1 latent construct was not associated with MetSyn
even when using different combinations of SNPs to devise
the construct (data not shown). The MYO16 latent gene
construct was not associated with either BP or MetSyn
factors; and, for parsimony reasons, was dropped from the
final model shown in Figure 1. The association between
MetSyn and CHD was similar, but slightly attenuated in
the model with (bstd = 0.13 ± 0.04; p = 0.002) versus
without (bstd = 0.14 ± 0.03; p < 0.001) the seven genes.
Discussion
Results between approaches were similar in that CSMD1
SNPs were found to be associated with MetSyn when using
both the modified WHO definition (Approach 1) and the
factor scores (Approach 2). However, when evaluating
associations between each SNP and each individual
metabolic measure, the factor scores (Approach 2) pro-
duced fewer putative genes with ≥2S N P su s i n gap <0 . 0 0 1 .
Because we were most interested in defining putative genes
and not individual SNPs, weretained genes with ≥2S N P sa t
p < 0.001 versus correcting for multiple tests using a
standard Bonferroni correction approach. If we had applied
a correction factor for 2,000 tests (p ≤ 2.5 × 10
-5), which is
the approximate number of genes on the 50 k panel, only
CETP (mean SNP p =1 . 0 5×1 0
-6) would have qualified for
use in Approach 3. Interestingly, the CETP latent gene
construct (Approach 3) had the strongest association of all
ofthegeneconstructsintermsofeffectsize(bstd=0. 15 )a nd
significance (p =1 . 0 4×1 0
-8) in the 7-gene, 24-SNP model
(Figure 1).
Figure 1
Model of the MetSyn and genes as latent constructs using SEM. Model resulted in good overall model fit
(c
2 = 1336.00, df = 457, p < 0.05; CFI = 0.02; RMSEA = 0.03; SRMR = 0.03). Standardized loadings and corresponding
standard errors are depicted above arrows. Blue, MetSyn traits; Red, Genes; Green, coronary heart disease;
*p ≤ 0.05; **p ≤ 0.10. Residuals not shown for clarity.
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Approaches 1 and 2, the CSMD1 latent gene construct
(Approach 3) was not associated with Metsyn when
modeled in the presence of SNPs in six other genes, even
when devising the construct with different combinations
of SNPs, which emphasizes an important advantage of
Approach 3 in that it can better control for the effects of
multiple putative SNPs (and genes) in the same model.
Although sample sizes differed between approaches, the
consistent findings we observed across all three
approaches for CETP (HDL (Approach 1), Lipids
(Approach 2)) and STARD13 (fasting glucose (Approach
1), Insulin Resistance (Approach 3)) make attributing
the CSMD1 discrepancies to sample size differences less
compelling. Moreover, SNPs in genes previously shown
to be associated with MetSyn using the WHO criteria,
including LDLR, PPARG,a n dACE [18], were not found
to be significant at p ≤ 0.05 in our study. The lack of
replication may be due to modifications we had to make
to the WHO definition to accommodate available data
and, perhaps, genetic heterogeneity of this complex
phenotype.
Conclusion
The multivariate framework of SEM is inherently better
suited for modeling the hierarchical, complex relations
involved in MetSyn; and, the latent gene construct SEM
approach appears particularly useful for disentangling
the influence of individual genes on MetSyn in the
presence of multiple putative SNPs.
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